SCHEMBL4457007

SCHEMBL4457007

OC(c1cc(F)cc(F)c1)c1cc(F)cc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.50
CES1 P23141 3/20 0.50
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA9 Q16790 1/20 0.45
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
CYP3A4 P08684 3/20 0.33
CYP2D6 P10635 3/20 0.33
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
SLC6A3 Q01959 3/20 0.33
MDM2 Q00987 1/20 0.32
BRD4 O60885 2/20 0.31
NR3C1 P04150 1/20 0.31
HDAC4 P56524 1/20 0.30
HDAC7 Q8WUI4 1/20 0.30
HDAC5 Q9UQL6 1/20 0.30
PTGS1 P23219 1/20 0.30
PTGS2 P35354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21831203 0.87 NR3C1 (0.44) CES2CES1CA12CA1CA9
SCHEMBL12065137 0.85 IDO1 (0.50) CES2CES1CA12CA1CA9
SCHEMBL230516 0.83 CES2 (0.50) CES2CES1IDO1TDO2SLC6A2
SCHEMBL28274632 0.77 CES2 (0.46) CES2CES1CA12CA1CA9
SCHEMBL4066383 0.77 CES2 (0.46) CES2CES1CA12CA1CA9
SCHEMBL4094087 0.77 CES2 (0.46) CES2CES1CA12CA1CA9
SCHEMBL1321039 0.77 CES2 (0.46) CES2CES1CA12CA1CA9
SCHEMBL1154665 0.77 CES2 (0.46) CES2CES1CA12CA1CA9
SCHEMBL14992168 0.76 POLB (0.35) CES2CES1
SCHEMBL8078157 0.74 CES2 (0.37) CES2CES1CYP3A4CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1443083-B1 Pearlescent pigments based on selectively absorbing layers of chalcogenide, oxychalcogenide and mixed chalcogenides MERCK PATENT GMBH (DE) 2008-02-27 EP claimed
EP-3850594-B1 VALUABLE DOCUMENT SYSTEM GIESECKE & DEVRIENT CURRENCY TECHNOLOGY GMBH (DE) 2026-03-11 EP disclosed
US-11664093-B2 Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-05-30 US disclosed
EP-3850594-A1 VALUABLE DOCUMENT SYSTEM Giesecke+Devrient Currency Technology GmbH (DE) 2021-07-21 EP disclosed
WO-2020052812-A1 VALUABLE DOCUMENT SYSTEM GIESECKE+DEVRIENT CURRENCY TECHNOLOGY GMBH (DE) 2020-03-19 WO disclosed
US-7576088-B2 Benzodioxole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
EP-1490691-B1 LUMINESCENT, SPHEROID, NON-AUTOFLUORESCENT SILICA GEL PARTICLES HAVING VARIABLE EMISSION INTENSITIES AND FREQUENCIES MAGNAMEDICS GMBH (DE) 2009-01-21 EP disclosed
EP-1532132-B1 NOVEL BENZODIOXOLES HOFFMANN LA ROCHE (CH) 2008-03-19 EP disclosed
US-20050143373-A1 Benzodioxole derivatives ALANINE ALEXANDER (FR) 2005-06-30 US disclosed
US-6900227-B2 Benzodioxole derivatives HOFFMANN-LA ROCHE INC. (US) 2005-05-31 US disclosed
EP-1532132-A1 NOVEL BENZODIOXOLES F.HOFFMANN-LA ROCHE AG (CH) 2005-05-25 EP disclosed
EP-1490691-A2 LUMINESCENT, SPHEROID, NON-AUTOFLUORESCENT SILICA GEL PARTICLES HAVING VARIABLE EMISSION INTENSITIES AND FREQUENCIES Müller-Schulte, Detlef P. (DE) 2004-12-29 EP disclosed
US-20040142922-A1 Benzodioxole derivatives HOFFMANN-LA ROCHE INC. 2004-07-22 US disclosed
WO-2004013120-A1 NOVEL BENZODIOXOLES F. HOFFMANN-LA ROCHE AG (CH) 2004-02-12 WO disclosed
WO-2003083481-A2 LUMINESCENT, SPHEROID, NON-AUTOFLUORESCENT SILICA GEL PARTICLES HAVING VARIABLE EMISSION INTENSITIES AND FREQUENCIES MUELLER-SHULTE DETLEF P (DE) 2003-10-09 WO disclosed
US-5153211-A Enzyme inhibitors ALCON LABORATORIES, INC. (US) 1992-10-06 US disclosed
US-5070100-A COMPLICATIONS OF DIABETES ALCON LABORATORIES, INC. (US) 1991-12-03 US disclosed
US-4864028-A ANTIDIABETIC AGENTS ALCON LABORATORIES, INC. (US) 1989-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143373-A1 Benzodioxole derivatives CNR2, CNR1, GPR119 CES2 197/4885CES1 229/4885CA12 3791/4885
US-20040142922-A1 Benzodioxole derivatives CNR1, CNR2, GPR119 CES2 214/4885CES1 47/4885CA12 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.